Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 217.91B +18.6% |
| Revenue (ttm) | 45.38B +6.3% |
| Net Income | 10.86B +5.2% |
| EPS | 5.60 +9.5% |
| Shares Out | 1.83B |
| PE Ratio | 21.26 |
| Forward PE | 16.58 |
| Dividend | 3.70 (3.11%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 1,318,560 |
| Open | 118.02 |
| Previous Close | 119.04 |
| Day's Range | 118.02 - 122.16 |
| 52-Week Range | 91.20 - 131.00 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 123.59 (+1.32%) |
| Earnings Date | Jul 21, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NOVN stock is "Hold." The 12-month stock price target is CHF 123.59, which is an increase of 1.32% from the latest price.
News
Novartis (NVS) Achieves Key Milestones in Muscle Dystrophy Treatment Study
Novartis (NVS) Achieves Key Milestones in Muscle Dystrophy Treatment Study
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Novartis announces biomarker cohort in study of del-brax met primary endpoint
Novartis (NVS) announced that the biomarker cohort of the Fortitude Phase I/II study of del-brax met its primary and key secondary endpoints, with reductions in KHDC1L and creatine kinase biomarker…
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous resul...
Novartis (NVS) Teams Up with Orionis Biosciences for Drug Development
Novartis (NVS) Teams Up with Orionis Biosciences for Drug Development
Novartis, Orionis enter collaboration for molecular glue medicines
Orionis Biosciences announced a multi-year collaboration with Novartis (NVS) to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. The collabor...
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year ...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido® (remibrutinib) clinical trial...
Novartis AG (NVS) Shares Surge 3.3% -- What GF Score of 81 Tells Investors
Novartis AG (NVS) Shares Surge 3.3% -- What GF Score of 81 Tells Investors
Novartis (NVS) Shows Promising Phase III ALIGN Study Results for Kidney Treatment
Novartis (NVS) Shows Promising Phase III ALIGN Study Results for Kidney Treatment
Novartis Vanrafia Data Show Clinically Meaningful Kidney Protection In IgA Nephropathy
(RTTNews) - Novartis AG (NVS) reported final results from the Phase III ALIGN study showing that Vanrafia slowed kidney function decline over 2.5 years in adults with IgA nephropathy (IgAN). The findi...
Novartis reports final 2.5-year Phase III ALIGN results on Vanrafia
Novartis (NVS) reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia versus placebo in adults with IgA nephropathy. Results were published in The Lancet ...
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Basel, June 4, 2026 – Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia® (atrasentan) versus placebo in adults with IgA nephropathy (IgAN)1 ...
Novartis Cosentyx Shows Sustained Remission In Polymyalgia Rheumatica
(RTTNews) - Novartis AG (NVS) announced new Phase III data for Cosentyx in polymyalgia rheumatica, published in the New England Journal of Medicine and presented at the 2026 EULAR Congress. The result...
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Basel, June 3, 2026 – Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rheumatica (PMR) demonstrating a statistically significant, clinically meaningful difference in sustained...
Positive Long-Term Results for Scemblix in CML Trials (NVS)
Positive Long-Term Results for Scemblix in CML Trials (NVS)
Novartis announces 144-week data from ASC4FIRST trial of Scemblix
Novartis (NVS) announced positive 144-week data from the ASC4FIRST trial of Scemblix presented at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. These results provide longer-ter...
Novartis Pluvicto And Actinium Program Advance Radioligand Therapy In Prostate Cancer
(RTTNews) - Novartis AG (NVS) presented new subgroup analyses from its pivotal PSMAddition Phase 3 trial, showing that Pluvicto (lutetium Lu 177 vipivotide tetraxetan) plus standard of care (SoC) cons...
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on Ju...
Novartis (NVS) Shows Promising Results in Prostate Cancer Treatment
Novartis (NVS) Shows Promising Results in Prostate Cancer Treatment
Novartis announces results on rPFS improvements across subgroups with Pluvicto
Novartis (NVS) announced results showing consistent radiographic progression-free survival, rPFS, improvement across key subgroups with Pluvicto plus standard of care compared to SoC alone in PSMA-pos...
Experimental Novartis radiopharma drug shows promise in early study
Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older...
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Basel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide tetr...
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year's European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce ...
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European ...